Memphasys (FRA:IG7) Short-Term Debt : €2.39 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Memphasys Short-Term Debt?

Memphasys's Short-Term Debt for the quarter that ended in Dec. 2023 was €2.39 Mil.

Memphasys's quarterly Short-Term Debt increased from Dec. 2022 (€2.35 Mil) to Jun. 2023 (€2.82 Mil) but then declined from Jun. 2023 (€2.82 Mil) to Dec. 2023 (€2.39 Mil).

Memphasys's annual Short-Term Debt increased from Jun. 2021 (€0.12 Mil) to Jun. 2022 (€2.37 Mil) and increased from Jun. 2022 (€2.37 Mil) to Jun. 2023 (€2.82 Mil).

Memphasys Short-Term Debt Historical Data

The historical data trend for Memphasys's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Memphasys Short-Term Debt Chart

Memphasys Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Debt

Get a 7-Day Free Trial

0.20

0.02

0.12

2.37

2.82

Memphasys Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															2.25	2.37	2.35	2.82	2.39

Memphasys Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Memphasys Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Memphasys's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Memphasys (FRA:IG7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Memphasys Ltd (FRA:IG7) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

MEM:Australia

Address

30 Richmond Road, Homebush, Sydney, NSW, AUS, 2140

Website

https://www.memphasys.com

Memphasys Ltd is an Australian-based emerging small-cap reproductive biotechnology company. It develops and commercializes novel reproduction and fertility solutions for humans and animals. Its technology includes Hydrogel and other polymer membrane technology development. The company is developing novel medical devices, diagnostics, and media with applications to assisted reproduction technologies, including IVF in humans and artificial insemination in animals.

Memphasys (FRA:IG7) Headlines

No Headlines